NRx Pharmaceuticals, Inc. (NRXP) Stock Price & Analysis
NRx Pharmaceuticals, Inc. (NRXP) closed at USD 2.71 on Thursday, October 15, 2026, up 4.63% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.59; the Oct 15, 2026 session ranged USD 2.48–2.77 on volume of 1,177,417 shares. Market capitalization is $117.33M, with a 52-week range of USD 1.62–5.06 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NRXP.md
Key facts (NRXP)
- Last four reported quarters (through Jun 30, 2026): revenue $3.4M, net income -$23.5M (-691.8% margin) (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 38.5 (range 10–50).
- Total return with dividends: 1Y -10.9% vs S&P 500 +18.1%; 5Y -97.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.15, revenue estimate $1.3M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NRXP)
| USD | FY2021 | FY2022 | FY2024 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0K | $0K | $1.2M | $3.4M |
| Gross profit | — | — | — | $0K | $720K | — |
| Operating income | -$116M | -$44.3M | -$27.8M | -$18.5M | -$16.2M | -$19.9M |
| Net income | -$93.1M | -$39.8M | -$30.1M | -$25.1M | -$28.6M | -$23.5M |
| EPS (diluted) | -$19.80 | -$6.00 | — | — | — | — |
| Free cash flow | -$37.7M | -$39.8M | -$21.7M | -$10.6M | — | — |
| Gross margin | — | — | — | — | 58.8% | — |
| Operating margin | — | — | — | — | -1324.4% | -586.2% |
| Net margin | — | — | — | — | -2336.5% | -691.8% |
| Cash + short-term investments | $27.6M | $20.1M | $4.6M | $1.4M | $7.8M | — |
| Total debt | — | $10.5M | $18.3M | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NRXP)
P/S 34.6x · Earnings yield -20.01%
Analysts (NRXP)
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 38.5 (low 10, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | Ascendiant Capital | Target raised | Buy | $49 → $50 |
| 2026-09-14 | BTIG | Reiterated | Buy | $10 |
| 2026-08-25 | HC Wainwright & Co. | Reiterated | Buy | $45 |
| 2026-08-18 | BTIG | Reiterated | Buy | $10 |
| 2026-08-07 | BTIG | Target lowered | Buy | $25 → $10 |
Total return (dividends reinvested) (NRXP)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -10.9% | -97.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -10.9% | -51.6% |
| Volatility (annualized) | 82.6% | 111.2% |
| Max drawdown | -49.2% (Oct 2025→Feb 2026) | -98.8% (Oct 2021→Nov 2024) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 2.71 |
|---|---|
| Change | ▲ 4.63% (up) |
| Previous Close | USD 2.59 |
| Open | USD 2.53 |
| Day Range | USD 2.48 – 2.77 |
| 52-Week Range | USD 1.62 – 5.06 |
| Volume | 1,177,417 shares |
| Market Cap | $117.33M |
| Exchange | NCM |
Technical Analysis (NRXP)
Nexqual's technical model rates NRXP "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 30.89 (neutral) |
| vs SMA50 | Below (USD 3.24) |
| MACD | -0.17 (negative) |
Analyst Ratings (NRXP)
Wall Street analysts rate NRXP "Buy" based on 4 analysts, with a mean price target of USD 38.5 (range USD 10–50), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 38.5 |
| High Target | USD 50 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (NRXP)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $1.29M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.24 vs est -0.13 ▼ miss |
| 2026-03-31 | USD -0.04 vs est -0.11 ▲ beat |
| 2025-12-31 | USD 0.18 vs est -0.08 ▲ beat |
| 2025-09-30 | USD -0.51 vs est -0.02 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (NRXP)
| Total Revenue | $3.39M |
|---|---|
| Gross Margin | +46.64% |
| Operating Margin | -590.46% |
| Profit Margin | +0.00% |
| Current Ratio | 0.86 |
| Total Cash | $26.69M |
| Total Debt | $834,000 |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (NRXP)
Nexqual rates NRx Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $27M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$14M (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — No data |
Ownership (NRXP)
| Insider Ownership | +4.12% |
|---|---|
| Institutional Ownership | +27.13% |
| Shares Outstanding | 43.30M |
| Float | 37.39M |
| Short % of Float | +23.59% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (NRXP)
NRx Pharmaceuticals, Inc. is led by Jonathan C. Javitt M.D., M.P.H. (age 68), Co-Founder, Chairman & CEO, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Co-Founder, Chairman & CEO | Jonathan C. Javitt M.D., M.P.H. (age 68) |
|---|---|
| CFO & Treasurer | Michael S. Abrams (age 55) |
| Chief Operating Officer | Joseph M. Casper (age 74) |
| Chief Development Officer & Director | Michael Taylor (age 50) |
| Chief Strategy Officer & Director | Dennis K. McBride (age 70) |
Major Backers & Investors (NRXP)
Notable institutional backers of NRx Pharmaceuticals, Inc. include B Group, Inc. , Ameriprise Financial, Inc., Balyasny Asset Management LP, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| B Group, Inc. | 9.45% |
| Ameriprise Financial, Inc. | 2.15% |
| Balyasny Asset Management LP | 2.06% |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 1.86% |
| Citadel | 1.57% |
| AdvisorShares Investments, LLC | 1.52% |
| Commonwealth Equity Services, LLC | 1.05% |
| UBS Group AG | 0.98% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.43% |
| BlackRock | 0.75% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. | USD 74.53 | ▼ 3.93% |
| DFTX | Definium Therapeutics, Inc. | USD 34.26 | ▼ 0.35% |
| MANE | Veradermics, Incorporated | USD 115.07 | ▼ 1.02% |
| ORKA | Oruka Therapeutics, Inc. | USD 73.87 | ▼ 5.53% |
| SRRK | Scholar Rock Holding Corporatio | USD 40.64 | ▲ 0.3% |
| TVTX | Travere Therapeutics, Inc. | USD 52.79 | ▲ 1.91% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt